Tranexamic Acid's Effects in Patients Undergoing Laparoscopic Radical Prostatectomy
NCT ID: NCT05816668
Last Updated: 2023-04-18
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
PHASE3
Total Enrollment
122 participants
Study Classification
INTERVENTIONAL
Study Start Date
2023-04-30
Study Completion Date
2024-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study is randomized, placebo-controlled, double-blind clinical trial that aims to check whether tranexamic acid's use in videolaparoscopic radical prostatectomy intraoperative is effective in decrease serum hemoglobin drop and the amount of blood's transfusion.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intraprostatic Injection of Tranexamic Acid Decrease Blood Loss During Monopolar TURP
NCT05913466
Benign Prostatic Hyperplasia
Transurethral Resection of the Prostate
Tranexamic Acid
UNKNOWN
NA
Tranexamic Acid in Urologic Surgery
NCT00670345
Bleeding
Prostatectomy
COMPLETED
PHASE4
Effect of Tranexamic Acid on Intraoperative Blood Loss in Patients Undergoing Aquablation
NCT06710327
Benign Prostatic Hyperplasia
NOT_YET_RECRUITING
PHASE4
Tranexamic Acid in Reducing Blood Loss in Patients With Pelvic Tumors Undergoing Hemipelvectomy Surgery
NCT03128866
Pelvic Mass
RECRUITING
EARLY_PHASE1
The Effects of Tranexamic Acid or Placebo on Perioperative Bleeding in Adults Undergoing Liver Transplantation.
NCT04753151
Hemorrhage
UNKNOWN
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study aims to check whether tranexamic acid's use in videolaparoscopic radical prostatectomy intraoperative is effective in decrease serum hemoglobin drop and the amount of blood's transfusion.
Therefore it will be a randomized, placebo-controlled, double-blind clinical trial that intends to recruit 122 patients with radical prostatectomy indication who agreed to consent study inclusion.
Patients randomized to intervention group will receive 1,0g of tranexamic acid IV during anesthetic induction, followed by a maintenance dose of 1,0 mg/kg/hour of surgery. Control group will be operated normally.
Data as hemoglobin drop, estimated bleeding volume, need to transfusion, side effects, and presence of lymphocele will be compared between the two groups.
Therefore it will be a randomized, placebo-controlled, double-blind clinical trial that intends to recruit 122 patients with radical prostatectomy indication who agreed to consent study inclusion.
Patients randomized to intervention group will receive 1,0g of tranexamic acid IV during anesthetic induction, followed by a maintenance dose of 1,0 mg/kg/hour of surgery. Control group will be operated normally.
Data as hemoglobin drop, estimated bleeding volume, need to transfusion, side effects, and presence of lymphocele will be compared between the two groups.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Prostate Cancer
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
PREVENTION
Blinding Strategy
TRIPLE
Participants
Caregivers
Investigators
Just ICESP's Clinical Research Pharmacy team will be not blinded. The surgical and anesthetic teams will be blinded in relation to the placebo or tranexamic acid intervention during the preoperative period and during the postoperative follow-up and, if any case loses the blinding, it will be excluded from the analysis. The preparation of packaging, dilution and dispensing or the material containing tranexamic acid or placebo will be carried out by the ICESP's Clinical Research Pharmacy division.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tranexamic Acid Group
Patients will receive an attack solution of 1,0 g of tranexamic acid 20 minutes before the surgery beginning, followed by a maintence dose of 1,0 mg/kg/h in pump surgery infusion
Group Type
EXPERIMENTAL
Tranexamic acid
Intervention Type
DRUG
Patients with prostate cancer and radical video laparoscopy prostatectomy indication will receive 1,0g of Tranexamic Acid solution IV in bolus 20 minutes before of anesthetic induction, followed by a maintenance hose of 1,0mg/kg/h of surgery.
Placebo Group
Patients undergoinf to videolaparoscopic surgery will receive physcological saline as placebo under the same conditions of the tranexamic acid group.
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
OTHER
Patients randomized to placebo group will receive physiological saline and will undergo to the radical video laparoscopu prostatectomy normally
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tranexamic acid
Patients with prostate cancer and radical video laparoscopy prostatectomy indication will receive 1,0g of Tranexamic Acid solution IV in bolus 20 minutes before of anesthetic induction, followed by a maintenance hose of 1,0mg/kg/h of surgery.
Intervention Type
DRUG
Placebo
Patients randomized to placebo group will receive physiological saline and will undergo to the radical video laparoscopu prostatectomy normally
Intervention Type
OTHER
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Transamin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients over 18 years olds;
* Who accept to participate and sign the consent form;
* Compliance with the study follow-up protocol;
* Diagnosed with localized prostate cancer with surgical indication without or with lymphadenectomy.
* Who accept to participate and sign the consent form;
* Compliance with the study follow-up protocol;
* Diagnosed with localized prostate cancer with surgical indication without or with lymphadenectomy.
Exclusion Criteria
* Coronary artery disease treated with drug-using stent;
* Previous coronary procedures or coronary disease using a stent;
* Acute or chronic liver failure;
* Severe chronic renal failure (ClCr \< 30 mL/Kg.h, according to the Modification of Diet in Renal Disease formula);
* Suspected allergy to tranexamic acid;
* Known coagulopathies and refusal to sign consent form.
* Previous coronary procedures or coronary disease using a stent;
* Acute or chronic liver failure;
* Severe chronic renal failure (ClCr \< 30 mL/Kg.h, according to the Modification of Diet in Renal Disease formula);
* Suspected allergy to tranexamic acid;
* Known coagulopathies and refusal to sign consent form.
Minimum Eligible Age
18 Years
Eligible Sex
MALE
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Instituto do Cancer do Estado de São Paulo
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
CAIO BRAMBILLA
MD
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rafael Ferreira Coelho, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Instituto do Câncer do Estado de São Paulo
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
Reference Type
BACKGROUND
Etzioni R, Tsodikov A, Mariotto A, Szabo A, Falcon S, Wegelin J, DiTommaso D, Karnofski K, Gulati R, Penson DF, Feuer E. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control. 2008 Mar;19(2):175-81. doi: 10.1007/s10552-007-9083-8. Epub 2007 Nov 20.
Reference Type
BACKGROUND
Tsodikov A, Gulati R, Heijnsdijk EAM, Pinsky PF, Moss SM, Qiu S, de Carvalho TM, Hugosson J, Berg CD, Auvinen A, Andriole GL, Roobol MJ, Crawford ED, Nelen V, Kwiatkowski M, Zappa M, Lujan M, Villers A, Feuer EJ, de Koning HJ, Mariotto AB, Etzioni R. Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. Ann Intern Med. 2017 Oct 3;167(7):449-455. doi: 10.7326/M16-2586. Epub 2017 Sep 5.
Reference Type
BACKGROUND
D'Amico AV, Whittington R, Malkowicz SB, Cote K, Loffredo M, Schultz D, Chen MH, Tomaszewski JE, Renshaw AA, Wein A, Richie JP. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer. 2002 Jul 15;95(2):281-6. doi: 10.1002/cncr.10657.
Reference Type
BACKGROUND
Bekelman JE, Rumble RB, Chen RC, Pisansky TM, Finelli A, Feifer A, Nguyen PL, Loblaw DA, Tagawa ST, Gillessen S, Morgan TM, Liu G, Vapiwala N, Haluschak JJ, Stephenson A, Touijer K, Kungel T, Freedland SJ. Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline. J Clin Oncol. 2018 Nov 10;36(32):3251-3258. doi: 10.1200/JCO.18.00606. Epub 2018 Sep 5.
Reference Type
BACKGROUND
Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, Fanti S, Fossati N, Gandaglia G, Gillessen S, Grivas N, Grummet J, Henry AM, van der Kwast TH, Lam TB, Lardas M, Liew M, Mason MD, Moris L, Oprea-Lager DE, van der Poel HG, Rouviere O, Schoots IG, Tilki D, Wiegel T, Willemse PM, Cornford P. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2021 Feb;79(2):243-262. doi: 10.1016/j.eururo.2020.09.042. Epub 2020 Nov 7.
Reference Type
BACKGROUND
Rainwater LM, Segura JW. Technical consideration in radical retropubic prostatectomy: blood loss after ligation of dorsal venous complex. J Urol. 1990 Jun;143(6):1163-5. doi: 10.1016/s0022-5347(17)40215-1.
Reference Type
BACKGROUND
Ramsay C, Pickard R, Robertson C, Close A, Vale L, Armstrong N, Barocas DA, Eden CG, Fraser C, Gurung T, Jenkinson D, Jia X, Lam TB, Mowatt G, Neal DE, Robinson MC, Royle J, Rushton SP, Sharma P, Shirley MD, Soomro N. Systematic review and economic modelling of the relative clinical benefit and cost-effectiveness of laparoscopic surgery and robotic surgery for removal of the prostate in men with localised prostate cancer. Health Technol Assess. 2012;16(41):1-313. doi: 10.3310/hta16410.
Reference Type
BACKGROUND
Basiri A, de la Rosette JJ, Tabatabaei S, Woo HH, Laguna MP, Shemshaki H. Comparison of retropubic, laparoscopic and robotic radical prostatectomy: who is the winner? World J Urol. 2018 Apr;36(4):609-621. doi: 10.1007/s00345-018-2174-1. Epub 2018 Jan 23.
Reference Type
BACKGROUND
Rassweiler J, Hruza M, Teber D, Su LM. Laparoscopic and robotic assisted radical prostatectomy--critical analysis of the results. Eur Urol. 2006 Apr;49(4):612-24. doi: 10.1016/j.eururo.2005.12.054. Epub 2006 Jan 18.
Reference Type
BACKGROUND
Ilic D, Evans SM, Allan CA, Jung JH, Murphy D, Frydenberg M. Laparoscopic and robotic-assisted versus open radical prostatectomy for the treatment of localised prostate cancer. Cochrane Database Syst Rev. 2017 Sep 12;9(9):CD009625. doi: 10.1002/14651858.CD009625.pub2.
Reference Type
BACKGROUND
Mohler JL, Antonarakis ES, Armstrong AJ, D'Amico AV, Davis BJ, Dorff T, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Ippolito JE, Kane CJ, Kuettel MR, Lang JM, McKenney J, Netto G, Penson DF, Plimack ER, Pow-Sang JM, Pugh TJ, Richey S, Roach M, Rosenfeld S, Schaeffer E, Shabsigh A, Small EJ, Spratt DE, Srinivas S, Tward J, Shead DA, Freedman-Cass DA. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 May 1;17(5):479-505. doi: 10.6004/jnccn.2019.0023.
Reference Type
BACKGROUND
Tewari A, Srivasatava A, Menon M; Members of the VIP Team. A prospective comparison of radical retropubic and robot-assisted prostatectomy: experience in one institution. BJU Int. 2003 Aug;92(3):205-10. doi: 10.1046/j.1464-410x.2003.04311.x.
Reference Type
BACKGROUND
Ficarra V, Novara G, Artibani W, Cestari A, Galfano A, Graefen M, Guazzoni G, Guillonneau B, Menon M, Montorsi F, Patel V, Rassweiler J, Van Poppel H. Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a systematic review and cumulative analysis of comparative studies. Eur Urol. 2009 May;55(5):1037-63. doi: 10.1016/j.eururo.2009.01.036. Epub 2009 Jan 25.
Reference Type
BACKGROUND
CRASH-2 trial collaborators; Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewan Y, El-Sayed H, Gogichaishvili T, Gupta S, Herrera J, Hunt B, Iribhogbe P, Izurieta M, Khamis H, Komolafe E, Marrero MA, Mejia-Mantilla J, Miranda J, Morales C, Olaomi O, Olldashi F, Perel P, Peto R, Ramana PV, Ravi RR, Yutthakasemsunt S. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010 Jul 3;376(9734):23-32. doi: 10.1016/S0140-6736(10)60835-5. Epub 2010 Jun 14.
Reference Type
BACKGROUND
Napolitano LM, Cohen MJ, Cotton BA, Schreiber MA, Moore EE. Tranexamic acid in trauma: how should we use it? J Trauma Acute Care Surg. 2013 Jun;74(6):1575-86. doi: 10.1097/TA.0b013e318292cc54. No abstract available.
Reference Type
BACKGROUND
Lin ZX, Woolf SK. Safety, Efficacy, and Cost-effectiveness of Tranexamic Acid in Orthopedic Surgery. Orthopedics. 2016 Mar-Apr;39(2):119-30. doi: 10.3928/01477447-20160301-05. Epub 2016 Mar 4.
Reference Type
BACKGROUND
Claeys MA, Vermeersch N, Haentjens P. Reduction of blood loss with tranexamic acid in primary total hip replacement surgery. Acta Chir Belg. 2007 Jul-Aug;107(4):397-401. doi: 10.1080/00015458.2007.11680081.
Reference Type
BACKGROUND
Dietrich W, Spannagl M, Boehm J, Hauner K, Braun S, Schuster T, Busley R. Tranexamic acid and aprotinin in primary cardiac operations: an analysis of 220 cardiac surgical patients treated with tranexamic acid or aprotinin. Anesth Analg. 2008 Nov;107(5):1469-78. doi: 10.1213/ane.0b013e318182252b.
Reference Type
BACKGROUND
MACFARLANE RG. AN ENZYME CASCADE IN THE BLOOD CLOTTING MECHANISM, AND ITS FUNCTION AS A BIOCHEMICAL AMPLIFIER. Nature. 1964 May 2;202:498-9. doi: 10.1038/202498a0. No abstract available.
Reference Type
BACKGROUND
DAVIE EW, RATNOFF OD. WATERFALL SEQUENCE FOR INTRINSIC BLOOD CLOTTING. Science. 1964 Sep 18;145(3638):1310-2. doi: 10.1126/science.145.3638.1310.
Reference Type
BACKGROUND
Wang YL, Jiang B, Yin FF, Shi HQ, Xu XD, Zheng SS, Wu S, Hou SC. Perioperative Blood Transfusion Promotes Worse Outcomes of Bladder Cancer after Radical Cystectomy: A Systematic Review and Meta-Analysis. PLoS One. 2015 Jun 16;10(6):e0130122. doi: 10.1371/journal.pone.0130122. eCollection 2015.
Reference Type
BACKGROUND
Linder BJ, Frank I, Cheville JC, Tollefson MK, Thompson RH, Tarrell RF, Thapa P, Boorjian SA. The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy. Eur Urol. 2013 May;63(5):839-45. doi: 10.1016/j.eururo.2013.01.004. Epub 2013 Jan 11.
Reference Type
BACKGROUND
Kerkebe Lama M, Orellana Salinas NR, Flores Martinez JM, Olivares Gribbell RA, Storme Cabrera O, Fuentealba Sudy CA. [Prospective study and comparative of surgical and oncologic outcome between laparoscopic and retropubical radical prostatectomy]. Actas Urol Esp. 2009 Feb;33(2):167-71. doi: 10.1016/s0210-4806(09)74118-x. Spanish.
Reference Type
BACKGROUND
Drouin SJ, Vaessen C, Hupertan V, Comperat E, Misrai V, Haertig A, Bitker MO, Chartier-Kastler E, Richard F, Roupret M. Comparison of mid-term carcinologic control obtained after open, laparoscopic, and robot-assisted radical prostatectomy for localized prostate cancer. World J Urol. 2009 Oct;27(5):599-605. doi: 10.1007/s00345-009-0379-z. Epub 2009 May 7.
Reference Type
BACKGROUND
Ficarra V, Novara G, Fracalanza S, D'Elia C, Secco S, Iafrate M, Cavalleri S, Artibani W. A prospective, non-randomized trial comparing robot-assisted laparoscopic and retropubic radical prostatectomy in one European institution. BJU Int. 2009 Aug;104(4):534-9. doi: 10.1111/j.1464-410X.2009.08419.x. Epub 2009 Mar 5.
Reference Type
BACKGROUND
Remzi M, Klingler HC, Tinzl MV, Fong YK, Lodde M, Kiss B, Marberger M. Morbidity of laparoscopic extraperitoneal versus transperitoneal radical prostatectomy verus open retropubic radical prostatectomy. Eur Urol. 2005 Jul;48(1):83-9; discussion 89. doi: 10.1016/j.eururo.2005.03.026. Epub 2005 Apr 12.
Reference Type
BACKGROUND
Ou YC, Yang CR, Wang J, Cheng CL, Patel VR. Comparison of robotic-assisted versus retropubic radical prostatectomy performed by a single surgeon. Anticancer Res. 2009 May;29(5):1637-42.
Reference Type
BACKGROUND
Batagello CA, Vicentini FC, Monga M, Miller AW, Marchini GS, Torricelli FCM, Danilovic A, Coelho RF, Srougi M, Nahas WC, Mazzucchi E. Tranexamic acid in patients with complex stones undergoing percutaneous nephrolithotomy: a randomised, double-blinded, placebo-controlled trial. BJU Int. 2022 Jan;129(1):35-47. doi: 10.1111/bju.15378. Epub 2021 Jun 13.
Reference Type
BACKGROUND
Crescenti A, Borghi G, Bignami E, Bertarelli G, Landoni G, Casiraghi GM, Briganti A, Montorsi F, Rigatti P, Zangrillo A. Intraoperative use of tranexamic acid to reduce transfusion rate in patients undergoing radical retropubic prostatectomy: double blind, randomised, placebo controlled trial. BMJ. 2011 Oct 19;343:d5701. doi: 10.1136/bmj.d5701.
Reference Type
BACKGROUND
Balik M, Kosina J, Husek P, Brodak M, Cecka F. Safety and Efficacy of Using Tranexamic Acid at the Beginning of Robotic-Assisted Radical Prostatectomy in a Double-Blind Prospective Randomized Pilot Study. Acta Medica (Hradec Kralove). 2020;63(4):176-182. doi: 10.14712/18059694.2020.60.
Reference Type
BACKGROUND
Saravanan R, Venkatraman R, Karthik K, Pushparani A. [Efficacy of different doses and timing of tranexamic acid in major orthopedic surgeries: a randomized trial]. Braz J Anesthesiol. 2020 Jul-Aug;70(4):311-317. doi: 10.1016/j.bjan.2020.03.013. Epub 2020 Jul 8.
Reference Type
BACKGROUND
Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibanes E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009 Aug;250(2):187-96. doi: 10.1097/SLA.0b013e3181b13ca2.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NP2011/2021
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
The Effect of ACT and Tranexamic Acid on Bleeding in Cardiac Surgery
NCT06109155
RECRUITING
PHASE4
Study Of Tranexamic Acid For The Reduction Of Blood Loss In Patients Undergoing Major Abdominal Surgery
NCT00827931
COMPLETED
PHASE4
Efficacy of Tranexamic Acid in Preventing Post Operative Blood Loss in Bone Sarcoma Patient
NCT05427513
UNKNOWN
EARLY_PHASE1
The Effect of Human Prostate Tissue on Platelet Activation
NCT05059431
COMPLETED
Can the Prophylactic Administration of Tranexamic Acid Reduce Blood Loss After Robotic-assisted Radical Prostatectomy?
NCT04319614
COMPLETED
PHASE4
Impact of Tranexamic Acid on Red Blood Cell Transfusion in Spinal Surgery
NCT01258010
COMPLETED
NA
Tranexamic Acid in Intertrochanteric and Subtrochanteric Femur Fractures
NCT02580227
UNKNOWN
PHASE4
Efficacy and Safety of Tranexamic Acid in Cytoreductive Surgery for Ovarian Cancer
NCT04360629
COMPLETED
NA
Safety and Efficacy of Intravenous Tranexamic Acid in Endoscopic Transurethral Resections in Urology
NCT02653261
COMPLETED
PHASE4
Impact of Tranexamic Acid Use in Percutaneous Nephrolithotomy
NCT02966236
UNKNOWN
PHASE4
Tranexamic Acid Versus Placebo for Blood to Reduce Perioperative Bleeding Post-liver Resection
NCT01651182
COMPLETED
PHASE3
Tranexamic Acid Use for Bleeding Prevention in the Surgical Treatment of Metastatic Spinal Tumor in Lung Cancer Patients
NCT06023212
RECRUITING
PHASE1/PHASE2
Evaluation of the Efficacy and Safety of Single Dose Tranexamic Acid in Reducing Blood Loss During Colorectal Cancer Surgery
NCT03606785
COMPLETED
PHASE4
TXA Study in Major Oncologic Surgery
NCT01980355
COMPLETED
NA
Intravenous Tranexamic Acid and Intramyometrial Desmopressin Effect on Blood Loss During Laparoscopic Myomectomy.
NCT05517590
COMPLETED
NA
Reduction Bleeding in Laminectomy With Double Doses of Tranexamic Acid
NCT01643135
COMPLETED
PHASE4
Use of Tranexamic Acid in the Total Knee Arthroplasty.
NCT05919615
COMPLETED
NA
Tranexamic Acid Versus Placebo to Reduce Perioperative Bleeding After Major Hepatectomy
NCT00657384
TERMINATED
PHASE3
Tranexamic Acid in Major Vascular Surgery
NCT02335359
COMPLETED
PHASE4
Tranexamic Acid, Hemorrhage and Transfusions After Combined Aortic Valve Replacement and Coronary Artery Bypass Surgery.
NCT00375466
COMPLETED
NA
The Use of Tranexamic Acid (TXA) Intravenously, to Reduce Blood Loss in Proximal Femur Surgery
NCT02164565
WITHDRAWN
PHASE4
A Preliminary Study of a New Tranexamic Acid Dosing Schedule for Cardiac Surgery
NCT00588133
COMPLETED
PHASE3
Tranexamic Acid in Percutaneous Nephrolithotomy
NCT05947435
COMPLETED
NA
Acid Tranexamic Effectiveness in Reducing the Intraoperative Bleeding in Palatoplasty
NCT02422056
COMPLETED
PHASE4
Tranexamic Acid in Sleeve Gastrectomy
NCT05696951
COMPLETED
NA